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Aim and Objectives: To examine the concordance of the Libyan Pharmaceutical List of Essential Medicines
(LPLEM) with the World Health Organization Model List of Essential Medicines 2009 (WMLEM 2009).
Methods: The concordance between generic medicines listed in the WMLEM 2009 (standard reference list)
and the LPLEM 2006 (comparator list) was evaluated.
Results: The total number of Basic Essential Medicines (BEMs) listed on the WMLEM 2009 was 347. The
total number of generic medicines listed on the LPLEM was 584. Although the LPLEM has more listed
medicines, only 270 (77.6%) of BEMs from the WMLEM were listed as available. However, 25 of the 77
missing medicines were deemed to have appropriate alternatives. A total of 52 medicines from the WMLEM
2009 were therefore missing from the LPLEM. Discrepancies compared to the WMLEM 2009 were identified
in 15 out of 29 therapeutic sections. The highest discrepancy rate from the WMLEM 2009 was in the
anti-infective section (35 missing medicines). Missing BEMs were noted in many subclassifications of the anti-
infective medicines section, but omissions were particularly prevalent in the antibacterial medicines
subsection (11 missing medicines). Antituberculosis medications had the highest discrepancy rate for
antibacterial BEMs with one-third of the single medicines recommended by the WHO in the WMLEM 2009
not listed on the LPLEM. Of the 314 additional medicines on the LPLEM, 18 were deemed to be irrational
non-essential medicines.
Conclusion: The LPLEM does not include several essential medicines recommended by the WHO in the
WMLEM 2009. These discrepancies may have serious public health implications for management of some
infectious diseases, particularly, tuberculosis and HIV.
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A
National Essential Medicines List (NEML) is
central to the sound management and supply of
essential medicines to any society (1). Appro-
priate selection of essential medicines for a NEML has
been considered by the World Health Organization
(WHO) as the most cost-effective health intervention
after childhood immunization (2). The appropriate selec-
tion of medicines can assist with the management and
supply of medicines and, as a result, curb the financial
burden caused by pharmaceuticals on national health
budgets (3). According to the WHO, a NEML should
encompass a limited group of medicines that are of
proven safety, efficacy, and cost effectiveness (4). This
limited group of medicines has been named by the WHO
as essential medicines (2). Under ideal circumstances
essential medicines are defined within the national
context and according to the prevalent diseases and
conditions in a given society (5). Since this capacity is
limited in many developing countries (1), the WHO has
identified a subset of medicines to treat the world’s most
common diseases and conditions. This subset of medi-
cines is listed in the WHO model list of essential
medicines (WMLEM) and has been regularly updated
since 1977. Essential medicines listed in the WMLEM
represent the minimum number of medicines that
should be available within any fully functioning health
care system and need to be the foundation of any NEML
(2, 6).
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that strives for high standard health care services (7).
Historically, the Libyan national standard list of medi-
cines was used by the public pharmaceutical sector of the
Libyan health care system (8, 9) for the procurement and
government subsidy of medicines for Libyan society.
Medicines are also supplied by the private pharmaceu-
tical market; however, access to medicines from the
private market is often prohibitively expensive.
The Libyan national standard list of medicines, which
was commonly known as the Libyan Pharmaceutical List
(LPL), was previously the list of all registered medicines
used in the Libyan health care system (8). Since the LPL
was too extensive to use for the general procurement of
medicines, government subsidy, and also encompassed
several unsafe and superseded medicines, it had been
implicated by local researchers (8, 9) and the WHO (7) as
a contributor to the problem of medicines management
and supply in Libya. As a result, the LPL was cancelled
by the National Committee of Drugs (7) and replaced by
a new Libyan national standard list of medicines  the
Libyan Pharmaceutical List of Essential Medicines
(LPLEM) in 2006. According to the Directorate of
Pharmacy and Medical Equipment in the Libyan Min-
istry of Health, the LPLEM 2006 encompassed only
essential medicines (rather than all registered medicines
in the health system) as advocated by the WHO. The
LPLEM 2006 continues to be the current Libyan national
standard list for procurement and government subsidy of
medicines.
The continuing problem of medicines management and
supply to Libyan society has been acknowledged by the
Libyan Government in several recent press releases (10).
Therefore, the aim of this study was to examine the
LPLEM 2006 in relation to compliance with the WHO
recommendations for medicines selection in order to
identify or exclude the LPLEM 2006 as a potential
contributor to the suboptimal management and supply
of essential medicines in Libya.
Methods
The concordance between the WMLEM 2009 and the
LPLEM 2006 was compared based on the method
utilized by Jafarov (11). All medicines listed in the
WMLEM 2009 were considered as Basic Essential
Medicines (BEMs) since they represent the minimum
formulary of medicines that should be available for a
country’s health care system. Both the core medicines list
and complementary medicines list were reviewed. The
core medicines list details medicines that meet the
minimum needs for a basic health care system, whereas
the complementary medicines list catalogues drugs used
for priority diseases for which specialized diagnostic or
monitoring facilities, specialist medical care, and/or
specialist training are needed.
Generic medicine concordance
The WMLEM 2009 was used as the standard reference
list for comparison (including the therapeutic sections)
and the LPLEM 2006 was the subject list. Since both lists
were not fully super imposable, a spreadsheet was
constructed to allow head-to-head comparison. Informa-
tion in relation to both lists was inserted in a comparative
matrix that allowed for evaluation of available BEMs
(medicines from the WMLEM 2009 that were available
on the LPLEM based on generic name), missing BEMs
(medicines from the WMLEM 2009 that were not
available on the LPLEM based on generic name),
additional available medicines (medicines on the LPLEM
but not listed on the WMLEM 2009), or alternative
available medicines. A medicine was deemed by the
reviewers to be an alternative available medicine to a
listed BEM from the WMLEM 2009 based on either
being in the same pharmacological class (e.g. tetracaine
and oxybuprocaine) or if having an ‘equivalent’ thera-
peutic action (e.g. DL-methionine and N-acetylcysteine).
If a medicine was listed in more than one therapeutic
section (e.g. morphine was listed in both the analgesics
and anesthetics sections) or was available in an alter-
native therapeutic section, the medicine was recorded as
available.
Formulation and dosage reconciliation for
available Basic Essential Medicines (BEMs)
For available BEMs, the number of product formulations
and strengths were identified and reconciled as follows:
1. Available BEMs that were presented in the LPLEM
in total concordance with those recommended by
the WHO in the WMLEM 2009.
2. Available BEMs that were presented in the LPLEM
with less or more dosage forms and/or product




The total number of medicines listed in the WMLEM
2009 was 347. The total number of medicines listed on the
LPLEM was 584. Based on generic identification of
counterparts from both lists, the LPLEM complied fully
with the recommendations of the WHO with regards to
essential medicines in 14 of the 29 standard therapeutic
sections. Detailed information in relation to number of
available BEMs per therapeutic section is illustrated in
Table 1.
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From the list of 347 BEMs on the WMLEM 2009, only
270 (78%) BEMs were listed as available on the LPLEM.
Missing Basic Essential Medicines (BEMs) for
which alternatives were available
Based on direct generic medicine concordance with the
WMLEM 2009, 77 (22%) of medicines recommended by
the WHO in the WMLEM 2009 were therefore missing
from the LPLEM (missing BEMs). However, for 25
(32%) of these missing BEMs therapeutic, alternatives
were available via another known channel of supply
within the Libyan health system, were culturally unac-
ceptable, or irrelevant to the Libyan disease demographic.
In more detail:
1. Eight (10%) of the missing BEMs have therapeutic
alternatives on the LPLEM. Of these, five had
alternatives that are chemically different but are
from the same pharmacological class (e.g. tetracaine
and oxybuprocaine), while three BEMs had an
alternative drug that could be considered therapeu-
tically similar (e.g. DL-methionine and N-acetyl
cysteine).
2. Some medicines from the dermatological section
(n7), endocrine section (n1), vitamins and
minerals section (n1), and the ear nose and throat
conditions in the children section (n1) were not
listed on the LPLEM. However, these products are
available on request as extemporaneously manufac-
tured products (e.g. potassium permanganate 1 in
10,000 solution, benzoic acid 3%/Salicylic acid 6%
ointment, etc.) and have therefore been omitted from
the missing BEMs group (see Table 2).
3. Some endocrine contraceptives products (n3) and
oxytocics (n1) are not included on the LPLEM for
cultural or legal reasons (see Table 2).
4. Some therapeutic substances (oxygen gas and etha-
nol) are supplied by other Libyan government
bodies of medical supply (9).
5. The Japanese encephalitis vaccine (n1) is irrele-
vant to the Libyan national disease profile.
In summary, there were 52 missing BEMs from the
WMLEM 2009 that were not listed as available on the
LPLEM. Theses medicines are listed in Table 3.
Missing Basic Essential Medicines (BEMs)
Missing BEMs (see Table 3) were distributed over 15 out
of 29 standard therapeutic sections with the highest
number of missing medicines in the anti-infective section
(n35). Missing BEMs from the anti-infective medicines
section (see Table 4) were distributed over various
subsections with the highest recorded discrepancy in the
antibacterial medicines subsection (n11). One-third of
antituberculosis medications recommended by the WHO
in the WMLEM 2009 were not listed on the LPLEM. In
addition, all fixed dose combinations recommended by
the WMLEM were not listed on the LPLEM.
Six out of seven missing BEMs from the antiviral
subsection were antiretroviral medicines. Of these, four
were fixed dose combinations and two were single
medicines. Nine medicines were also missing from the
antiprotozoal subsection.


















Blood products 4 0
Cardiovascular 19 0
Dermatological 21 10
Diagnostic agents 6 0
Disinfectants 6 1
Diuretics 5 0
Electrolytes and water 8 0
Endocrine 21 6




Muscle relaxants 5 1
Ophthalmological 10 1
Oxytocics 5 1






Vitamins and minerals 11 3
Total
a 387 77
aDuplicates exist among different therapeutic sections.
ENT: ear, nose, and throat.
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Pharmaceutical List of Essential Medicines (LPLEM)
After review there were 314 medicines on the LPLEM
deemed to be additional. Of these, 274 were classified
under the same therapeutic sections adopted by the
WHO in the WMLEM 2009. However, of these 274
medicines, 18 were deemed by the reviewers to be non-
essential medicines (see Table 5). Forty of the additional
medicines listed on the LPLEM fall outside the peri-
meters of the classification system for BEMs used by the
WHO. These products include dietary supplements,
pharmaceutical chemicals, and rodenticides.
Formulation and dosage reconciliation for available
Basic Essential Medicines (BEMs)
Of 270 available BEMs, 172 were presented in the
LPLEM in total concordance with those recommended
by the WHO in the WMLEM 2009, 67 were presented in
the LPLEM with less dosage forms and/or product
strengths than those recommended by the WHO in the
WMLEM 2009, and 31 were presented in the LPLEM
with more dosage forms and/or product strengths than
those recommended by the WHO in the WMLEM 2009.
Discussion
According to the WHO guidelines, a NEML is central to
medicine’s management and supply for any society (1).
However, in order for a NEML to contribute positively to
the national medicines situation, medicines on the list
must first be selected appropriately. Full discussion of the
ideal process of medicines selection is beyond the scope of
this paper. However, the WHO states that appropriate
selection of medicines for a NEML is a process that
requires several tenets to be carefully considered (2).
Firstly, medicines need to be selected from a pool of safe
and effective medicines underpinned by a sound medicine
registration system (1). Secondly, medicines on the
NEML should reflect the treatment requirements of
nationally prevalent diseases that have been identified
and examined by a robust epidemiological reporting
Table 2. Missing BEMs for which alternatives were identiﬁed
Therapeutic section Number Missing BEMs Alternatives
Anesthesia 1 Oxygen gas Supplied by alternate provider
a
Antidotes 1 DL-methionine N-acetylcysteine
Anti-infective 2 Cefotaxime Ceftazidime Ceftriaxone
ImipenemCilastin Meropenem
Dermatological 7 Benzoic acidsalicylic acid Gentian
violet Potassium permanganate




Disinfectants 1 Ethanol Supplied by alternate provider
a
Endocrine 3 Diaphragms with spermicide
(nonoxinol) Condoms with or
without spermicide (nonoxinol)
Copper-containing device
Private sector based on cultural reasons
1 Lugol’s solution Extemporaneous preparation
b
ENTconditions in children 1 Acetic acid Extemporaneous preparation
b
Gastrointestinal 2 Aluminum hydroxide Magnesium
hydroxide
Magnesium trisilicate 250 mg with dried
aluminum hydroxide gel 100 mg tabs
Immunologicals 1 Japanese encephalitis vaccine Irrelevant to Libyan morbidity profile
Ophthalmological 1 Tetracaine Oxybuprocaine
Oxytocics 1 Mifepristone-misoprostol Culturally unacceptable
Psychotropic 1 Fluphenazine decanoate Flupenthixol decanoate




aAvailable via other channels of supply for medical equipment and chemicals.
bAvailable as an extemporaneous preparation.
ENT: ear, nose, and throat.
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accordingly, national health indicators that reflect mor-
bidity and mortality trends must be available (2). In
addition, other supportive measures need to be imple-
mented. A national system to identify microbial resistance
patterns, as well as educational and government processes
to provide personnel well trained in current therapeutics,
morbidity trends, critical appraisal, and pharmacoeco-
nomics (12) need to implemented. As stated by local
researchers, the capacity to perform such tasks in Libya
needs to be improved (8, 9).
Since epidemiological data regarding the Libyan
national disease profile is not readily available (7, 13),
the LPLEM was evaluated in comparison to the
WMLEM as a potential contributor to medicine avail-
ability problems in Libya. The WHO recommends that
all medicines listed on the WMLEM be available in any
fully functioning health system (2) unless the medicine is
legally unacceptable, culturally improper, or irrelevant to
the national disease profile (14). The analysis demon-
strated that the LPLEM fully complied with medicines
recommended by the WHO in the WMLEM 2009 in 14
out of 29 therapeutic sections. However, many BEMs
were not listed as available in other therapeutic sections.
Even after considering possible therapeutic alternatives,
there were 52 missing BEMs from the LPLEM. There
was one BEM not listed in the gastrointestinal, muscle
relaxant, vitamins and minerals, specific medicines for
neonatal care, and medicines for ear nose and throat
conditions in children therapeutic sections; two BEMs
not listed in the endocrine, immunological, and psycho-
tropic therapeutic sections; and three BEMs not listed in
the antidotes and dermatological therapeutic sections.
The area of greatest concern was the anti-infective
section, where 35 medicines from the WMLEM were not
listed on the LPLEM. The WHO states that several
communicable diseases such as tuberculosis, HIV/AIDS,
malaria, and leishmaniasis still impose a threat to Libyan
society (7, 13)
It is important to reinforce that risks imposed by
suboptimal anti-infective medicine selection have the
capacity to extend well beyond an individual patient
(15). The LPLEM was suboptimal in relation to inclusion
of essential anti-infective medicines from the WMLEM
2009 for all subsections of anti-infective medicines. The
highest recorded discrepancy from the anti-infective
section was with antituberculosis medicines (see Table 4).
Antituberculosis medicines recommended in the
WMLEM 2009 are either single medicines or fixed dose
combinations. Four single medicines, including the first-
lineantituberculosismedicine,rifabutin,werenotlistedon
the LPLEM. Five first-line antituberculosis fixed dose
combinations were also not listed on the LPLEM (see
Table 4). Although all individual medicines included in







Potassium ferric hexacyano-ferrate(II) 2H2O
(Prussian blue)
Antidotes 14 3 Sodium nitrite
Sodium thiosulfate
Anti-infective 107 35 Multiple/Table 4
Dermatological 21 3 Aluminum diacetate Selenium sulfide Permethrin
Endocrine 21 2 Ethinylestradiol Estradiol cypionate
medroxyprogesterone acetate
ENT conditions in children 4 1 Xylometazoline
Gastrointestinal 14 1 Zinc sulfate
Immunologicals 26 2 Varicella vaccine
Rotavirus vaccine
Muscle relaxants 5 1 Alcuronium chloride




4 1 Caffeine citrate
Vitamins and minerals 11 1 Thiamine
52
ENT: ear, nose and throat.
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this does not necessarily provide the best mechanism to
ensure treatment effectiveness, patient compliance, and
does not eliminate the need for fixed dose combinations
(16, 17). Fixed dose combinations of antituberculosis
medicines offer several advantages since they reduce the
number of capsules or tablets that must be ingested daily,
decrease the likelihood of resistance, improve clinical
outcomes, enhance patient compliance, simplify treatment
regimens, and facilitate logistics (16, 18, 19). Fixed dose
combinations can only be excluded in settings where the
WHO recommendations in relation to tuberculosis treat-
ment (e.g. the Directly Observed Short Course, DOTS,
strategy) are strictly implemented (17, 18). Nevertheless,
even in such settings, fixed dose combinations enhance
patient compliance by decreasing ‘pill burden’ (18). The
importance of providing thebest available pharmaceutical
products, including fixed dose combinations to treat
tuberculosis, is reinforced by evidence of a substantial
increase in the number of reported tuberculosis cases over
the last 15 years in Libya (20). In addition, although
information from the WHO Libyan country profile (13)
indicates the existence of multidrug resistant tuberculosis,
three out of seven treatments recommended by the WHO
Table 4. Missing BEMs from the anti-infective medicines section
Therapeutic subsection
Total number of medicines
listed in the WMLEM 2009
Number of missing
medicines Missing medicines


















Antifungal 7 1 1. flucytosine
Antiviral medicines 21 7 1. emtricitabine(FTC)
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notlistedontheLPLEM.Alsoofconcernisthecontinued
listing of thiocetazone (as an additional medicine anti-
tuberculosis in the medicines section on the LPLEM), a
drug whose use is diminishing due to safety concerns and
questionable efficacy (21). Thiocetazone hasweak activity
against Mycobacterium tuberculosis and offers no advan-
tage over ethambutol (22).
Results from the comparative analysis demonstrated
another major discrepancy in the antiretroviral medicines
section. HIV/AIDS is not currently a major cause of
morbidity and mortality in Libya, however its incidence
is increasing among injecting drug users (7). Two single as
well as four fixed dose combinations were missing from
the LPLEM (see Table 4). As with tuberculosis treatment,
fixed dose combinations reduce pill burden, minimize
(prescribing, dispensing, and use) errors, and improve
logistics (23). Triple antiretroviral combinations employ-
ing fixed dose combinations are the most convenient and
affordable options for treatment (16).
The analysis of the antiprotozoal subsection demon-
stratedthatoneofthreeBEMs(paronomycin)usedforthe
treatment of leishmania infections (see Table 4) is missing
from the LPLEM. Leishmaniasis is endemic in some areas
of the Libyan nation (24) and is an increasing problem not
only in Libyabut also in the whole African continent (10).
ThreeBEMsusedtotreatmalariaarealsonotlistedonthe
LPLEM.Althoughmalariaisnotamajordiseaseproblem
in Libya (7) since isolated cases still require treatment, all
BEMs to treat malaria should be available.
Missing BEMs from the LPLEM that have implica-
tions for children and neonatal care (n4), include
caffeine citrate and rotavirus vaccine. Caffeine citrate is
preferred to aminophylline for the treatment neonatal
apnea of prematurity due to a better adverse effect
profile and a longer elimination half-life (25), and hence
should also be listed on the LPLEM. Rotavirus vaccine is
a major cause of childhood diarrhea in Libya (26) and is
highly recommended by the WHO to be included
in national immunization programs. Clinical trials of
rotavirus vaccine in high-mortality, low-socioeconomic
settings of South Africa and Malawi have found that the
vaccine significantly reduced severe diarrhea episodes due
to rotavirus (27).
Another area of concern is antidote medicines.
Although uncommon, thallium and cyanide poisonings
are potentially life threatening (28, 29). Prussian blue,
the antidote of choice for treatment of thallium toxicity
(30) as well as sodium nitrite and sodium thiosulfate to
treat cyanide poisoning (31), need to be listed on the
LPLEM.
Of 21 dermatological medicines, 3 were missing from
the LPLEM (see Table 4). The inclusion of malathion on
the LPLEM (within the group of additional medicines)
does not eliminate the need for permethrin. No signifi-
cant difference exists in regarding their efficacy against
head lice (32) and permethrin requires less application
time and is a safer alternative in most cases.
The 2002 definition of essential medicines (2) clearly
states that there is no upper limit for inclusion of
medicines on a NEML; however, the definition set out
by the WHO clearly indicates that the optimization of
essential medicines be the principal priority (2). The
LPLEM included a high number of additional medicines
(n274) that exceeded the number of essential medicines
onthelist(n270).Thisgroupofadditionalmedicineson
the LPLEM included some medicines that weredeemed to
be non-essential. Some of the non-essential medicines
couldbeconsideredobsoletesince newer alternativesfrom
the same class exist on the LPLEM. Specific examples
include nalidixic acid and tetracycline. Nalidixic acid has
been superseded by other quinolones (33) while doxycy-
cline has largely replaced tetracycline worldwide (34). The
inclusion of the fixed dose combination of chlordiazep-
oxide and clidinium bromide cannot be justified in 2010 as
a necessary product for a NEML. The LPLEM also
included additional medicines with poor safety profiles
such as maprotiline, a third-line tetracyclic antidepressant
with a higher epileptogenic potential than many alter-
native antidepressants available on the LPLEM (35).
This study of the generic concordance of medicines
between the LPLEM and the WMLEM 2009 did not
reconcile product (dosage forms and dosage strengths)
discrepancies among both lists. For example, pyrazina-
mide was deemed as an available BEM on the LPLEM;
however, pyrazinamide was listed only as a 500 mg tablet,
whereas the WMLEM 2009 recommends multiple for-
Table 5. Non-essential medicines identiﬁed in the LPLEM
Antibiotic and corticosteroid
combinations in the eye section
(four different products)
Nicoumalone 1 mg tablet
Antihemorrhoidal ointment Noscapine linctus 15 mg/





Chlordiazepoxide 5 mg with
clidinium bromide 2.5 mg tablets
Pentazocine lactate
30 mg/ml ampoules




Dihydrocodeine tartarate 30 mg
tablets
Ritodrine hydrochoride
10 mg/5 ml ampoules








Mercurochrome Tiaprid 100 mg tablets
Nalidixic acid 500 mg tablets Trometamol 7% solution
Analysis of LPLEM and WHO model list of essential medicines
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tablet, 150 mg dispersible tablets, and 150 mg scored
tablets). The review of appropriate dosage form and
strength selection is also an important aspect of rational
selection of medicines for NEMLs that requires further
research.
The discrepancies between the LPLEM 2006 and the
WMLEM 2009 highlight the need for continual review of
the LPLEM. Future discrepancies can be prevented if the
list is reviewed continually or at least annually.
Conclusion
This analysis of the LPLEM in reference to the WMLEM
2009 has several implications for medicines management
and supply in Libya. In order to cater for the essential
medicines needs of the Libyanhealth system, all aspectsof
appropriate medicine selections advocated by the WHO
need to be considered. The establishment of a standar-
dized evidence-based process of medicines selection that
complies with the WHO recommendations is the one and
only avenue that can systematically build a robust NEML
that fulfils the societal needs of medicines. The anti-
infective section in the LPLEM has demonstrated the
highest discrepancy from the WHO recommendations
and requires urgent review. In addition, the LPLEM still
includes several medicines with safety concerns or with
minimal evidence of clinical efficacy. The entire process of
development and updating the LPLEM requires further
consideration and improvement.
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